Eli Lilly & Co. has not given up hope of finding a disease-modifying treatment for Alzheimer's disease, despite many failed attempts, including the recently discontinued Phase III program for the beta secretase cleaving enzyme (BACE) inhibitor lanabecestat. [Sidebar#SC123243]
In fact, Lilly Research Labs President Daniel Skovronsky said in an interview on June 13 – the day after the...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
